Clinical Research Directory
Browse clinical research sites, groups, and studies.
Endometrial Response in Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate
Sponsor: CMH Kharian Medical College
Summary
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age, characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology. Letrozole, an aromatase inhibitor, has emerged as a first-line ovulation induction agent due to its superior ovulation and pregnancy rates compared to clomiphene citrate. Estradiol valerate, a synthetic estrogen, can be co-administered with letrozole to improve endometrial receptivity by enhancing endometrial thickness, vascularity, and pattern. This study aims to evaluate the effect of letrozole alone versus letrozole with estradiol valerate on endometrial development in these patients.
Official title: Endometrial Response in Women With Poorly Primed Endometrial Lining in Diagnosed Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate
Key Details
Gender
FEMALE
Age Range
20 Years - 35 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-03-05
Completion Date
2026-08-31
Last Updated
2026-01-30
Healthy Volunteers
No
Conditions
Interventions
Letrozole (Aromatase Inhibitors)
30 participants with PCOs will receive tab letrozole 2.5mg 2 x OD for 5 days
Letrozole (Aromatase Inhibitors) + Estradiol valerate
30 participants with PCOs will receive tab letrozole 2.5mg 2 x OD for 5 days plus tab Estradiol valerate 2mg OD for 12 days
Locations (1)
CMH Kharian Medical College
Khārian, Punjab Province, Pakistan